key: cord-0902491-xd4trqfq
authors: Canal-Rivero, M.; Catalán-Barragán, R.; Rubio-García, A.; Garrido-Torres, N.; Crespo-Facorro, B.; Ruiz-Veguilla, M.
title: The role of antipsychotics against COVID-19: A topic for debate
date: 2021-07-08
journal: Schizophr Res
DOI: 10.1016/j.schres.2021.07.003
sha: c8301cbc589202c14bb2e989fbc58ee5b7ce4142
doc_id: 902491
cord_uid: xd4trqfq

nan

To the editors, We are very grateful for the comments made to our publication "Lower risk of SARS-CoV-2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population" as well as to the Editors of Schizophrenia Research for the opportunity to response to the observations. The relevance of the impact of COVID-19 on mental health in the general population, healthcare workers, mental health users and health care system is unquestionable and needs to be discussed (Crespo-Facorro, 2020; Vieta et al., 2020) .

Firstly, we would like to emphasize that the publication derived from clinical observation in our own hospital. In particular, we noticed that severe mental health patients infected by SARS-CoV-2 who presented marked COVID-19 risk factors did not show bad prognosis. It is worth noting, that this clinical observation was also reported by other clinicians in other countries (Dratcu & Boland; Unpublished manuscript). On the other hand, the risk of COVID-19 infection and mortality in severe mental health patients in our catchment area was lower than reported in scientific literature.

The high prevalence of COVID-19 risk factors among mental health patients has been widely demonstrated. This information was not included due to the limitations of the publication format. In our study, we have only registered COVID-19 risk factors in those patients who were infected by SARS-CoV-2 (n=9). In particular, we observed that the prevalence of COVID-19 risk factors was as follows: 0% diabetes, 22.2% respiratory diseases, 11.1% dementia, 11.1% cardiovascular disease, 11.1% hypertension, 33,3% smokers or 44.4% obesity. Lastly, we agree with the observation that multivariate analyses allows to get more realistic and nearer to the reality. However, since the main aim of the letter was to describe the prevalence and prognosis of COVID-19 in severe mental health patients under LAI treatment we considered that bivariate analyses were appropriate for the purpose of the study.

In conclusion, and as was mentioned in the original letter, the results have to be taken judiciously. On the other hand, further studies are required to elucidate possible role of antipsychotic in preventing SARS-CoV-2 infection as well as its possible protective effects against detrimental courses of COVID-19. Finally, we would like to highlight that the publication of results that differ from those previously published do not call into question their veracity. In fact, it enriches the knowledge we have about the prevalence, prognosis and transmission of SARS-CoV-2 in people diagnosed with a severe mental disorder.

J o u r n a l P r e -p r o o f Journal Pre-proof

Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population

Mental health and the SARS-CoV-2 pandemic

Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis

Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study

The authors wish to thank Virgen del Rocío University Hospital team for their data collection and assistance with administration.J o u r n a l P r e -p r o o f Journal Pre-proof

All the authors have participated and have made substantial contributor for this paper.

The authors have no conflicts of interest concerning the subject of the study.